Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Prevention and risk

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background Definitions and diagnostic criteria for all medical conditions are regularly subjected to reviews and revisions as knowledge advances. In the field of Alzheimer's disease (AD) research, it has taken almost three decades for diagnostic nomenclature to undergo major re-examination. The shift towards presymptomatic and pre-dementia stages of AD has brought prevention and treatment trials much closer to each other than before. Methods Here we discuss: (i) the impact of diagnostic reliability on the possibilities for developing preventive strategies for AD; (ii) the scientific evidence to support moving from observation to action; (iii) ongoing intervention studies; and (iv) the methodological issues and prospects for balancing strategies for high-risk individuals with those for broad population-based prevention. Results The associations between neuropathology and cognition are still not entirely clear. In addition, the risk factors for AD dementia and the neuropathological hallmarks of AD may not necessarily be the same. Cognitive impairment has a clearer clinical significance and should therefore remain the main focus of prevention. Risk/protective factors for dementia/AD need to be studied from a life-course perspective. New approaches in prevention trials include enrichment strategies based on genetic risk factors or beta-amyloid biomarkers (at least four ongoing pharmacological trials), and multidomain interventions simultaneously targeting various vascular and lifestyle-related risk factors (at least three ongoing trials). Experience from prevention programmes in other chronic diseases can provide additional methodological improvements. Conclusions Building infrastructures for international collaborations is necessary for managing the worldwide public health problem of AD and dementia. The International Database on Aging and Dementia (IDAD) and the European Dementia Prevention Initiative (EDPI) are examples of ongoing international efforts aiming to improve the methodology of preventive studies and provide the basis for larger intervention trials.

What this study adds

Evidence grade: Low

This review discusses the shift toward presymptomatic and pre-dementia stages of Alzheimer's disease and notes that associations between neuropathology and cognition are still not entirely clear. It describes ongoing intervention studies and methodological issues but does not report results from a prevention trial.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Solomon, A., Mangialasche, F., Richard, E., Andrieu, S., Bennett, D. A., Breteler, M., et al. (2014). Advances in the prevention of Alzheimer's disease and dementia. Journal of internal medicine. https://doi.org/10.1111/joim.12178

Vancouver

Solomon A, Mangialasche F, Richard E, Andrieu S, Bennett DA, Breteler M, et al. Advances in the prevention of Alzheimer's disease and dementia. Journal of internal medicine. 2014. doi:10.1111/joim.12178. PMID: 24605807.

BibTeX

@article{solomon2014-24605807,
  author  = {Solomon, A. and Mangialasche, F. and Richard, E. and Andrieu, S. and Bennett, D. A. and Breteler, M. and Fratiglioni, L. and Hooshmand, B. and others},
  title   = {{Advances in the prevention of Alzheimer's disease and dementia}},
  journal = {Journal of internal medicine},
  year    = {2014},
  doi     = {10.1111/joim.12178},
  pmid    = {24605807},
  url     = {https://doi.org/10.1111/joim.12178}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This review discusses the shift toward presymptomatic and pre-dementia stages of Alzheimer's disease and notes that associations between neuropathology and cognition are still not entirely clear. It describes ongoing intervention studies and methodological issues but does not report results from a prevention trial.

Study details

How this study scored 52/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 6 of 7; Citations per year 4 of 5; Impact for its field and year 5 of 6; Cited by studies here 3 of 6; Still being cited 2 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 52 of 100.52 of 100 points earned48 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of internal medicine)
Journal's citation record 2 / 4 Journal of Internal Medicine: journal h-index 237 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2014 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 319 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 22.8 citations a year over 14 year(s) since 2014
Impact for its field and year 5 / 6 Cited 25.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 17 other studies in this library
Still being cited 2 / 4 Cited 35 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Miia Kivipelto: h-index 107 (OpenAlex, whole career)
Institution's track record 2 / 3 University of Southern California: institution h-index 1,521 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 12 institution(s) in 6 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 24605807)
Free to read 0 / 2 Behind a paywall — scores zero
Total 52 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 40.

Later studies that cite this one

17 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Prevention and risk from nearby years

Also in Prevention and risk

269 studies in the library are filed under Prevention and risk with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Prevention and risk hub.

Similar studies

More on Prevention and risk

See all studies in Prevention and risk →